Observational Study for Glioblastoma Multiforme and Radiation Therapy
This study is collecting blood and urine samples from people receiving radiation therapy for glioblastoma multiforme (a type of brain tumor). Researchers want to see how radiation affects blood cells and certain proteins, specifically VEGF (vascular endothelial growth factor) and MMPs (matrix metalloproteinases). The goal is to determine if changes in these protein levels after radiation therapy can predict if the tumor will return within one year. This information could help develop new ways to measure radiation exposure, improve cancer treatments, and identify which patients might respond best to radiation. You may be eligible if you are 18 years or older, have glioblastoma multiforme, and are a candidate for radiation therapy. The current recruitment status is unclear.
- Study design
- This is an observational study planning to enroll 200 participants. It is not a randomized or blinded study.
- What's involved
- You would be asked to provide blood and urine samples before, during, and after your radiation treatment.
- Compensation
- Not stated in the trial record.
- Follow-up
- The study aims to predict tumor recurrence at one year, suggesting follow-up for at least that duration.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Collection of Blood and Urine Samples in Patients Receiving Radiation Therapy for Glioblastoma Multiforme
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Kevin A Camphausen, M.D. · PRINCIPAL_INVESTIGATOR · National Cancer Institute (NCI)
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- To determine if an increase in urinary VEGF and MMP level, from the end of treatment to a patient's one-month follow-up examination following radiotherapy is predictive of one-year recurrence in patients with Glioblastoma multiformeone year
Determine the whether VEGF and MMP level measurements aid in predicting tumor recurrence at 1 year.